Cytomx Therapeutics Stock Cash Per Share
| CTMX Stock | USD 1.06 0.04 3.92% |
CytomX Therapeutics fundamentals help investors to digest information that contributes to CytomX Therapeutics' financial success or failures. It also enables traders to predict the movement of CytomX Stock. The fundamental analysis module provides a way to measure CytomX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytomX Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 2.36 | 2.25 |
CytomX | Cash Per Share |
CytomX Therapeutics Company Cash Per Share Analysis
CytomX Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current CytomX Therapeutics Cash Per Share | 2.94 X |
Most of CytomX Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CytomX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CytomX Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for CytomX Therapeutics is extremely important. It helps to project a fair market value of CytomX Stock properly, considering its historical fundamentals such as Cash Per Share. Since CytomX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CytomX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CytomX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
CytomX Cash Per Share Historical Pattern
Today, most investors in CytomX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CytomX Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CytomX Therapeutics cash per share as a starting point in their analysis.
CytomX Therapeutics Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
CytomX Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, CytomX Therapeutics has a Cash Per Share of 2.94 times. This is 32.41% lower than that of the Biotechnology sector and 32.1% lower than that of the Health Care industry. The cash per share for all United States stocks is 41.32% higher than that of the company.
CytomX Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytomX Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytomX Therapeutics could also be used in its relative valuation, which is a method of valuing CytomX Therapeutics by comparing valuation metrics of similar companies.CytomX Therapeutics is currently under evaluation in cash per share category among its peers.
CytomX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytomX Therapeutics from analyzing CytomX Therapeutics' financial statements. These drivers represent accounts that assess CytomX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytomX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 376.7M | 302.3M | 277.8M | 105.2M | 114.4M | 108.7M | |
| Enterprise Value | 213.2M | 135.3M | 90.3M | (70.4M) | 111.2M | 105.6M |
CytomX Fundamentals
| Return On Equity | -54.75 | ||||
| Return On Asset | 0.0233 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | (27.17 M) | ||||
| Shares Outstanding | 78.26 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 65.62 % | ||||
| Number Of Shares Shorted | 4.44 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 5.04 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 101.21 M | ||||
| Gross Profit | 53.16 M | ||||
| EBITDA | (4.31 M) | ||||
| Net Income | (569 K) | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 13.97 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (56.03 M) | ||||
| Short Ratio | 4.41 X | ||||
| Earnings Per Share | 0.16 X | ||||
| Price To Earnings To Growth | (1.80) X | ||||
| Target Price | 5.29 | ||||
| Number Of Employees | 120 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 79.82 M | ||||
| Total Asset | 201.79 M | ||||
| Retained Earnings | (723.45 M) | ||||
| Working Capital | 27.02 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
| Net Asset | 201.79 M |
About CytomX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytomX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytomX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytomX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.